AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipseudomonas human immunoglobulin
Number of subjects: 746
Study 6419315 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV‐01 plus immunoglobulin
Number of subjects: 746
Study 6419315 — intervention group
Group type: COMPARATOR
Intervention: No immunologic prophylaxis
Number of subjects: 746
Study 6419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic regimens (PEV‐01, immunoglobulin)
Number of subjects: 746
Study 30828771 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosed FXaI cocktail (rivaroxaban, apixaban, edoxaban at 100 µg total)
Number of subjects: 18
Study 30828771 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosed FXaI cocktail with ketoconazole
Number of subjects: 18
Study 30252519 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral treatment (CBT)
Number of subjects: 92
Study 30252519 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 92
Study 27235849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200mg/d)
Number of subjects: 19
Study 27235849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25262266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding after PCI
Number of subjects: 96637
Study 25262266 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion after bleeding
Number of subjects: 96637
Study 21194865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-stress dynamic real-time myocardial perfusion CT
Number of subjects: 20
Study 21194865 — intervention group
Group type: COMPARATOR
Intervention: Adenosine-stress first-pass dual-energy myocardial perfusion CT
Number of subjects: 20
Study 20182022 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatments (specific subclasses: calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin-AT1-receptor-blockers)
Number of subjects: 7
Study 20182022 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatments (placebo-controlled)
Number of subjects: 7
Study 18303097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose (120 mcg ipratropium bromide and 600 mcg of salbutamol using metered dose inhaler (MDI) and spacer)
Number of subjects: 25
Study 18303097 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (nebulized 500 mcg ipratropium bromide and 2.5 mg salbutamol)
Number of subjects: 25
Study 18303097 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 25
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Symptom Validity Test (MSVT)
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsterdam Short‐Term Memory Test (ASTM)
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT)
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Figure Test (CFT)
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit Span
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rey's 15‐Item‐Test (FIT)
Number of subjects: 36
Study 16005815 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT ratio TMT‐B:TMT‐A
Number of subjects: 36
Study 12492770 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine/Venlafaxine XR
Number of subjects: 0
Study 12492770 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0
Study 12492770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10071003 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS
Number of subjects: 60
Study 10071003 — intervention group
Group type: COMPARATOR
Intervention: sham-PENS
Number of subjects: 60
Study 10071003 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 60
Study 10071003 — intervention group
Group type: COMPARATOR
Intervention: exercise therapies
Number of subjects: 60
Study 7493304 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of rIFN‐alpha 2b for 6 months
Number of subjects: 39
Study 7493304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of rIFN‐alpha 2b for 6 months
Number of subjects: 39
Study 7493304 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed for six months)
Number of subjects: 39
Study 7493304 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients who completed rIFN‐alpha 2b treatment
Number of subjects: 39
Study 7493304 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients post-therapy
Number of subjects: 39
Study 7493304 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with a sustained response
Number of subjects: 39
Study 2170963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination low sodium, low fat, high fibre diet
Number of subjects: 193
Study 2170963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 193
Study 2170963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 193
Study 2170963 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre diet
Number of subjects: 193
Study 1091391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (15 gm/day)
Number of subjects: 92
Study 1091391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 1091391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride and Placebo
Number of subjects: 92
Study 31969134 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy High School (HHS) intervention programme
Number of subjects: 5976
Study 31006207 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous vaccination of hepatitis E and hepatitis B (292 subjects)
Number of subjects: 600
Study 31006207 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination (159 subjects)
Number of subjects: 600
Study 31006207 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis E vaccination (150 subjects)
Number of subjects: 600
Study 28705312 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle programs (weight reduction, increasing physical activity, smoking cessation)
Number of subjects: 824
Study 28705312 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner participation in the intervention group
Number of subjects: 824
Study 25581612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical remission (ACR/EULAR Boolean remission)
Number of subjects: 118
Study 25581612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Disease Activity Index (CDAI) remission
Number of subjects: 118
Study 25581612 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy or tumor necrosis factor plus methotrexate treatment
Number of subjects: 118
Study 25581612 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evidence of residual joint inflammation
Number of subjects: 118
Study 23506999 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 24
Study 23506999 — intervention group
Group type: EXPERIMENTAL
Intervention: nicotine
Number of subjects: 24
Study 23506999 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline and nicotine (combined)
Number of subjects: 24
Study 23506999 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 21812988 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health intervention care programs
Number of subjects: 0
Study 21812988 — intervention group
Group type: COMPARATOR
Intervention: Usual care programs
Number of subjects: 0
Study 21812988 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay at the centre for prevention and reactivation
Number of subjects: 0
Study 21812988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary teams
Number of subjects: 0
Study 19930853 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise programme
Number of subjects: 40
Study 19930853 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (control) group
Number of subjects: 40
Study 16829333 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary counseling via lay health advisors (promotoras) plus tailored print materials delivered via the mail
Number of subjects: 357
Study 16829333 — intervention group
Group type: COMPARATOR
Intervention: Tailored mailed print materials only
Number of subjects: 357
Study 16829333 — intervention group
Group type: COMPARATOR
Intervention: Targeted mailed 'off-the-shelf' materials
Number of subjects: 357
Study 12911358 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 55
Study 12911358 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 55
Study 10698229 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201
Number of subjects: 43
Study 10698229 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium 99m sestamibi
Number of subjects: 43
Study 10437178 — intervention group
Group type: EXPERIMENTAL
Intervention: Consciousness-restoring method
Number of subjects: 92
Study 10437178 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of acupuncture
Number of subjects: 92
Study 8386779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal injections with sodium bicarbonate (0.03 mEq.)
Number of subjects: 38
Study 8386779 — intervention group
Group type: COMPARATOR
Intervention: Intracorporeal injections without sodium bicarbonate
Number of subjects: 38
Study 3698595 — intervention group
Group type: EXPERIMENTAL
Intervention: Meteneprost 10 mg vaginal suppositories
Number of subjects: 40
Study 3698595 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppositories
Number of subjects: 40
Study 29165855 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face coaching
Number of subjects: 0
Study 29165855 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching
Number of subjects: 0
Study 29165855 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27501928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHC)
Number of subjects: 38
Study 27501928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHC use)
Number of subjects: 38
Study 24368433 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet
Number of subjects: 86
Study 24368433 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine LCn3s diet
Number of subjects: 86
Study 24368433 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diets
Number of subjects: 86
Study 24368433 — intervention group
Group type: COMPARATOR
Intervention: Control diet (poor in LCn3s and polyphenols)
Number of subjects: 86
Study 22549602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing
Number of subjects: 32
Study 22549602 — intervention group
Group type: COMPARATOR
Intervention: General activity pacing
Number of subjects: 32
Study 20586028 — intervention group
Group type: EXPERIMENTAL
Intervention: SCCA
Number of subjects: 70
Study 20586028 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR
Number of subjects: 70
Study 20586028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin D1
Number of subjects: 70
Study 20586028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1
Number of subjects: 70
Study 20586028 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR and Cyclin D1 (combined detection)
Number of subjects: 70
Study 17919762 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily injections of biphasic insulin aspart 30
Number of subjects: 160
Study 17919762 — intervention group
Group type: COMPARATOR
Intervention: Three-times-daily injections of insulin aspart with or without NPH insulin (multiple daily injections)
Number of subjects: 160
Study 15982125 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal stimulus-response arrangements
Number of subjects: 0
Study 15982125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical stimulus-response arrangements
Number of subjects: 0
Study 15982125 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments inducing shortening or lengthening of mean response time
Number of subjects: 0
Study 12394797 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 25
Study 10516450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bus drivers (long-term sitting)
Number of subjects: 50
Study 10516450 — intervention group
Group type: COMPARATOR
Intervention: Surgeons (control group, standing)
Number of subjects: 50
Study 7492123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 31
Study 7492123 — intervention group
Group type: COMPARATOR
Intervention: CMV immunoglobulin
Number of subjects: 31
Study 1958445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg daily for 2 days, then 20 mg daily for 8 days)
Number of subjects: 18
Study 1958445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7338423 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme during the first 3 months
Number of subjects: 30
Study 7338423 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme during the second 3 months
Number of subjects: 30
Study 7338423 — intervention group
Group type: COMPARATOR
Intervention: Physical training programme (both groups)
Number of subjects: 30
Study 31868632 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of R-CHOP plus two doses of rituximab
Number of subjects: 588
Study 31868632 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of R-CHOP
Number of subjects: 588
Study 28805757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin therapy combined with antihypertensive therapy
Number of subjects: 140
Study 28805757 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive therapy alone
Number of subjects: 140
Study 28805757 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 140
Study 25970667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention lasting 30 min over one academic year, led by preschool teachers with educational components for parents and teachers.
Number of subjects: 709
Study 25970667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention
Number of subjects: 709
Study 25970667 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 709
Study 23734250 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-AIT (1×4 min at 90% HRmax)
Number of subjects: 26
Study 23734250 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-AIT (4×4 min at 90% HRmax)
Number of subjects: 26
Study 21798134 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 50
Study 21798134 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methodology (Control)
Number of subjects: 50
Study 21798134 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on concept mapping
Number of subjects: 50
Study 19366386 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin Choice decision aid
Number of subjects: 22
Study 19366386 — intervention group
Group type: COMPARATOR
Intervention: Standard educational pamphlet
Number of subjects: 22
Study 15792142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronoran (piribedil) 50 mg per day for 30 days
Number of subjects: 30
Study 15792142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronoran (piribedil) 50 mg per day for 90 days
Number of subjects: 30
Study 11845364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needle introduction at the Neiguan point (Pe. 6)
Number of subjects: 51
Study 11845364 — intervention group
Group type: COMPARATOR
Intervention: Placebo point needle introduction
Number of subjects: 51
Study 11845364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture point (Neiguan)
Number of subjects: 51
Study 11845364 — intervention group
Group type: COMPARATOR
Intervention: Both acupuncture and placebo points
Number of subjects: 51
Study 10526806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (Group 1)
Number of subjects: 30
Study 10526806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-induced hypotension (Group 2)
Number of subjects: 30
Study 10526806 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 30
Study 7589011 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg day‐1)
Number of subjects: 6
Study 1771612 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ethylester compound of n‐3 fatty acids (3.15 g EPA and 1.89 g DHA daily)
Number of subjects: 20
Study 1771612 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ethylester compound of n‐3 fatty acids
Number of subjects: 20
Study 1771612 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 20
Study 1771612 — intervention group
Group type: COMPARATOR
Intervention: Concentrated ethylester compound of n‐3 fatty acids and Corn oil (control)
Number of subjects: 20
Study 6751736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride (50 mg three times daily)
Number of subjects: 18
Study 6751736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30461556 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Number of subjects: 91
Study 30461556 — intervention group
Group type: COMPARATOR
Intervention: American Cancer Society Web site (Control)
Number of subjects: 91
Study 28577583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 26
Study 26544055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative hydration system (2 glucose/electrolyte solutions - 'two bag system')
Number of subjects: 12
Study 26544055 — intervention group
Group type: COMPARATOR
Intervention: Traditional hydration system (1 glucose/electrolyte solution)
Number of subjects: 12
Study 23415619 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention for 3 months
Number of subjects: 21
Study 23415619 — intervention group
Group type: COMPARATOR
Intervention: Obese group (control)
Number of subjects: 21
Study 21537127 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB loaded with 50 mg doxorubicin
Number of subjects: 40
Study 21537127 — intervention group
Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 40
Study 19584739 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin 2 mg (PRM)
Number of subjects: 40
Study 19584739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17261960 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 232
Study 17261960 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 232
Study 16411342 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV information handout
Number of subjects: 490
Study 16411342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HIV information handout)
Number of subjects: 490
Study 11772811 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol bolus (1 mg/kg) and infusion (250 microg x kg(‐1) x min(‐1))
Number of subjects: 30
Study 11772811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9840471 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy (estradiol valerate combined with medroxyprogesterone acetate)
Number of subjects: 78
Study 9840471 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 78
Study 9840471 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 78
Study 7805982 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler ultrasound
Number of subjects: 28
Study 7805982 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 125 levels
Number of subjects: 28
Study 7805982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic morphological patterns
Number of subjects: 28
Study 7805982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of color Doppler and CA 125 or morphological assessments
Number of subjects: 28
Study 2505282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (Li+)
Number of subjects: 17
Study 2505282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 767094 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap operation
Number of subjects: 20
Study 767094 — intervention group
Group type: COMPARATOR
Intervention: Gingivectomy
Number of subjects: 20
Study 767094 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurement (4 weeks after surgery)
Number of subjects: 20
Study 31864574 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicate-substituted calcium phosphate (Si-CaP)
Number of subjects: 40
Study 31864574 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone graft
Number of subjects: 40
Study 31864574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Si-CaP and Autologous bone graft)
Number of subjects: 40
Study 31533827 — intervention group
Group type: EXPERIMENTAL
Intervention: P-LSM (pragmatic lifestyle modification)
Number of subjects: 1725
Study 31533827 — intervention group
Group type: COMPARATOR
Intervention: C-LSM (12-monthly lifestyle modification advice)
Number of subjects: 1725
Study 28339826 — intervention group
Group type: COMPARATOR
Intervention: HDF (hemodiafiltration)
Number of subjects: 1616
Study 28339826 — intervention group
Group type: COMPARATOR
Intervention: HD (hemodialysis)
Number of subjects: 1616
Study 25734485 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation card group
Number of subjects: 462
Study 25734485 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) group
Number of subjects: 462
Study 23733379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 540
Study 23733379 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 540
Study 21519744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 0
Study 21519744 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet
Number of subjects: 0